Pseudomonas aeruginosa bacteremia among immunocompetent and immunocompromised patients: Relation to initialantibiotic therapy and survival

Pseudomonas aeruginosa bacteremia occurs mainly in immunocompromised patients. However, P. aeruginosa bacteremia in immunocompetent patients has also been reported. The aim of this study was to evaluate the clinical characteristics of P. aeruginosa bacteremia in relation to the immune status of the patients. The medical records of 126 adult patients with P. aeruginosa bacteremia in Nagasaki University Hospital were retrospectively reviewed between January 2003 and December 2012. Of 126 patients with P. aeruginosa bacteremia, 60 patients (47.6z) were classified as immunocompetent. Mortality in immunocompetent patients tended to be lower than in immunocompromised patients (7-day mortality, 8z vs. 30z, P ＜ 0.01; 30-day mortality, 23z vs. 39z, P = 0.053). Multivariate analysis showed that a higher sequential organ failure assessment score (hazard ratio [HR]: 1.27, P ＜ 0.01) and underlying malignancies (HR: 3.33, P ＜ 0.01) were independently associated with 30-day mortality. Initial antibiotic therapy (HR: 0.21, P ＜ 0.01) and patients' immune status (HR: 0.29, P = 0.02) also had a significant impact on survival. However, there was a significant interaction between these 2 variables (P = 0.03 for interaction). A subgroup analysis showed that in immunocompromised, but not immunocompetent patients, initial appropriate antibiotic therapy was associated with lower mortality (30-day mortality 20.5z vs. 66.7z, P ＜ 0.01 by log-rank test).